Drug Database
MI

midazolam

✓ Approved

Rafa Laboratories Ltd · GABRA1 · 小分子

什么是 midazolam?

midazolam 是一种小分子,由Rafa Laboratories Ltd研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection。

药物档案

公司Rafa Laboratories Ltd
药物类别小分子
分子靶点GABRA1, GABRA2, GABRA3, GABRA4, GABRA5
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved

作用机制

分子靶点

midazolam 作用于 5 个分子靶点:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (DEE19, ECA4)
GABRA2gamma-aminobutyric acid type A receptor alpha2 subunit (DEE78, EIEE78)
GABRA3gamma-aminobutyric acid type A receptor alpha3 subunit (EPILX2)
GABRA4gamma-aminobutyric acid type A receptor alpha4 subunit ()
GABRA5gamma-aminobutyric acid type A receptor alpha5 subunit (EIEE79, DEE79)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

midazolam 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Nervous system disordersStatus epilepticus✓ Approved

相关研究文献

PubMedIranian journal of pharmaceutical research : IJPR2026-11-18

Adjunct Low-Dose Dexmedetomidine for Sedation in Mechanically Ventilated Children: An Exploratory Randomized Trial.

Farrokhian Amir A, Forouzan Najmeh N, Mirrahimi Bahador B, Hashemi Seyyedeh Masumeh SM et al.

Effective sedation in the pediatric intensive care unit (PICU) is complicated by the adverse effects of benzodiazepines and opioids. Dexmedetomidine may provide a benzodiazepine-sparing alternative with distinct pharmacologic properties. We hypothesized that adjunct, fixed low-dose, no-bolus dexmedetomidine would reduce midazolam and fentanyl exposure per ventilator-day in mechanically ventilated children. In a triple-blind randomized controlled trial, 60 mechanically ventilated patients aged 1 month to 12 years were randomized to standard sedation (continuous midazolam and fentanyl) plus low-dose dexmedetomidine (a fixed-rate continuous infusion at 0.2 µg/kg/h without a loading bolus) or matched placebo (0.9% normal saline). In both groups, midazolam and fentanyl were titrated per protocol to achieve the target Richmond Agitation-Sedation Scale (RASS) level. Among 60 randomized children, adjunct fixed low-dose dexmedetomidine did not reduce the prespecified primary outcome of fentanyl or midazolam exposure per ventilator-day. Median fentanyl exposure per ventilator-day was 70.0 µg·kg-1·day-1 in the control group and 90.6 µg·kg-1·day-1 in the dexmedetomidine group; median midazolam exposure per ventilator-day was 7.0 mg·kg-1·day-1 and 9.1 mg·kg-1·day-1, respectively. Neither primary comparison remained statistically significant after Holm correction. In an unadjusted secondary analysis, the median time to first successful extubation was 6 days in the dexmedetomidine group and 15 days in the control group. This finding was exploratory and was not confirmed by the prespecified competing-risk or longitudinal ventilation analyses. Adjunct fixed low-dose dexmedetomidine without a loading bolus did not reduce fentanyl or midazolam exposure per ventilator-day. Early sedative-analgesic exposure was higher with dexmedetomidine, and the apparent early-extubation signal was exploratory and was not confirmed by competing-risk or longitudinal analyses of ventilation.

PMID 43047987
阅读全文 →
PubMedExperimental animals2026-11-18

Flumazenil accelerates emergence from medetomidine-midazolam-butorphanol and dexmedetomidine-remimazolam-butorphanol anesthesia in mice.

Sasaki Takeru T, Watanabe Masaki M, Nakagawa Ryuya R, Ozaki Yui Y et al.

Injectable three-drug anesthesia in mice combines an α2-adrenoceptor agonist, a benzodiazepine and an opioid, as in the medetomidine-midazolam-butorphanol mixture and its newer variant, dexmedetomidine-remimazolam-butorphanol. Atipamezole, the usual reversal agent, antagonizes only the α2-adrenoceptor agonist, but does not directly reverse benzodiazepine-mediated activity. We examined whether adding the benzodiazepine antagonist flumazenil to atipamezole hastens emergence and alters post-anesthetic body temperature. Male C57BL/6JJcl mice received one of the two mixtures intraperitoneally and, 40 min later, atipamezole alone or with flumazenil (0.5 mg/kg each) in a 2 × 2 factorial design (n=6 per group). Flumazenil shortened the interval from antagonist administration to return of the righting reflex (RORR) by 4.54 min (95% CI, 1.93-7.15; P=0.002), with no anesthetic × antagonist interaction (P=0.62), although the study was not powered to establish equivalent effects between mixtures. Flumazenil approximately halved the temperature decline before RORR (P<0.001) without a detectable change in cooling rate (P=0.18), a pattern consistent with less time spent cooling rather than improved thermoregulation. Active warming was discontinued at antagonist administration in all groups, so the additional benefit under continued warming remains unknown. Later in recovery, temperature differences reflected the anesthetic mixture rather than the antagonist, dexmedetomidine-remimazolam-butorphanol-treated mice being 1.73°C warmer at the interpolated 220-min point (P=0.003). Adjunctive flumazenil hastened emergence under the tested conditions but does not replace thermal support and monitoring during recovery.

PMID 43051883
阅读全文 →
PubMedAnaesthesia and intensive care2026-11-18

Audit of procedural sedation in a remote Australian hospital 2010 - 2021.

Senevirathna Weragoda Ajantha WA, Mills Peter David PD, Nobre Fernanda F, Gonzalez-Chica David Alejandro DA

Procedural sedation is commonly provided in rural hospitals; however, there is little published safety data. The authors conducted a retrospective audit of anaesthetic records from 2010 to 2021 of procedural sedation in a remote hospital in South Australia. The data were collected from 1912 cases, which were provided mainly for gastroenterology procedures in day case theatre and emergency department settings. Sedation was provided by a general practitioner anaesthetist giving boluses of fentanyl, midazolam and propofol. All patients were low risk (American Society of Anesthesiologists physical status 1-3). There were few anaesthetic problems and no mortality during sedation or in the recovery area. The most common problem was desaturation requiring airway support and oxygen, and occurred in 2% of cases. Procedural sedation was practiced safely in this remote setting.

PMID 43049087
阅读全文 →
PubMedEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology2026-11-18

Age and sex related differences on genotype stratified CYP450 mediated metabolism rate in healthy populations; a systematic review.

Schaars K Kleine KK, Bedi S S, PSY-PGx Consortium, van Westrhenen R R

Variability in drug response is common, with up to 70% of patients experiencing insufficient efficacy or adverse drug reactions. While genetic polymorphisms in cytochrome P450 (CYP) enzymes explain part of this variability, factors such as sex and age may also be important. This systematic review summarizes evidence on sex- and age-related differences five CYP isoforms (CYP1A2, CYP3A4, CYP2C9, CYP2C19, and CYP2D6). A search in MEDLINE, PsycINFO, and Embase identified 23 studies combining CYP genotyping and phenotyping, of which 15 contributed to the sex analysis and 6 to the age analysis. Databases were searched up to 9 February 2026. Findings were heterogeneous, reflecting differences in study design, probe substrates, and genotyping panels. Some studies suggested higher CYP1A2 activity in males, while smoking was more consistently associated with higher activity. Oral contraceptive use was consistently associated with reduced enzyme activity in females. Limited midazolam-based evidence suggested modestly higher CYP3A activity in females, while one study reported discordant findings with endogenous markers. One study suggested a decrease in CYP3A activity with age. Limited evidence from two studies suggested lower CYP2C9 activity in females. For CYP2C19, results were mixed, but oral contraceptive use reduced activity and age-related decline was reported. Limited adult evidence suggested lower CYP2D6 activity in females within genotype groups. In infants, CYP2D6 activity was detectable early and remained relatively stable throughout the first year of life. Overall, sex- and age-related differences in CYP activity appear enzyme- and context-specific, but the heterogeneous evidence does not support sex- or age-based dose adjustment.

PMID 43051034
阅读全文 →
PubMedJournal of clinical psychopharmacology2026-11-18

The Role of Droperidol in the Management of Acute Agitation: A Comprehensive Review.

Gupta Srajan S, Patel Malav M, Jeelugu Sreshta S, Shah Hetansh H et al.

Acute behavioral disturbance accounts for ~1.7 million emergency department visits in the USA annually, with 83% involving an underlying serious mental illness. A 2001 FDA black box warning regarding QT prolongation reduced use of droperidol, a butyrophenone antipsychotic, but recent data challenge these concerns. We reviewed randomized controlled trials, systematic reviews, and observational studies from 2000 to 2025 assessing droperidol's efficacy and safety. Droperidol provides rapid, effective sedation, with onset within 3 to 10 minutes and median time to adequate sedation of 14 to 25 minutes. Sixty-four percent of patients achieved adequate sedation at 15 minutes with droperidol versus 25% to 35% with ziprasidone and 29% with lorazepam. QT prolongation occurred in 1.3% of 1009 patients, mostly those with pre-existing risk factors. Respiratory depression was less common with droperidol (12%) than with ziprasidone (36% to 39%) or lorazepam (48%). Droperidol-midazolam combinations achieved faster sedation and reduced need for rescue medications (41% vs. 62%). Droperidol-treated patients had shorter hospital stays. Large studies found negligible rates of torsades de pointes or extracardiac arrhythmias. Elderly and pediatric patients responded favorably to low-dose droperidol. The American College of Emergency Physicians now recommends droperidol as first-line treatment for severe agitation. Combined with benzodiazepines, droperidol shows synergistic effects and allows lower doses of both with fewer adverse effects. Recent evidence contradicts earlier FDA concerns, supporting droperidol as a safe, effective treatment for acute agitation. Its rapid onset, efficacy, safety profile, and operational benefits, including shorter ED stay, support its return to routine clinical practice.

PMID 43049443
阅读全文 →
PubMedJournal of anaesthesiology, clinical pharmacology2026-11-18

Opioid-free anesthesia versus opioid-based anesthesia on postoperative delirium incidence: A systematic review.

Jannati Belia O BO, Lestari Mayang I MI, Liberty Iche A IA

The use of opioids as anesthetic agents is associated with multiple adverse effects, such as delirium. Patients with postoperative delirium (POD) have a higher risk of mortality or major complications. Recently, a multimodal anesthetic technique known as opioid-free anesthesia (OFA) has been developed to minimize or eliminate the use of opioids during anesthesia, which is hypothesized to reduce the incidence of POD. This systematic review aims to compare OFA and opioid-based anesthesia (OBA) to the incidence of POD. Literature searches were conducted electronically without time restrictions across six databases: PubMed, Cochrane Central Register for Controlled Trials, ProQuest, ScienceDirect, Springer Nature, and PMC Europe. Additional studies were obtained through electronic searches on Google. The inclusion criteria were human studies involving participants aged ≥18 years, interventions of OFA and OBA, and POD as an outcome. Study selection was performed using Rayyan QCRI, and risk of bias was assessed using the Cochrane Risk of Bias 2 (RoB 2) and Risk of Bias in Non-randomized Studies - of Interventions (ROBINS-I). Six studies met the inclusion criteria; three randomized controlled trials (RCTs), two cohort studies, and one case-control study. Five studies demonstrated no significant difference in the incidence of POD between the OFA and OBA groups; one study reported no occurrence of POD in either group. Several factors influencing POD included advanced age, type and duration of surgery, and the pharmacological effects of anesthetic agents such as dexmedetomidine, lidocaine, midazolam, and regional analgesic agents. OFA has not been shown to clearly reduce the incidence of POD. The occurrence of POD is multifactorial.

PMID 43048211
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多midazolam